Objective: Scant clinical data are available on the effects of current treatments for asthma on different subgroups of patients with this disease. We conducted a prospective, noninterventional, multicenter real-life study in adult patients with persistent asthma, and we specifically analyzed the effects of treatment with extrafine beclometasone dipropionate/formoterol (BDP/F) in asthma patients categorized by phenotypes related to small airways (i.e. smoking habits, disease duration, and air trapping). Methods: Patients received BDP/F as a fixed combination (100/6 μg), administered in 1–2 inhalations twice daily over a period of 12 weeks. Peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC),...
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases char...
SummaryBackgroundLung deposition is crucial for asthma treatment. However, there is no study compari...
BACKGROUND: Combinations of a long-acting beta(2)-agonist (LABA) and an inhaled corticosteroid (ICS)...
Background: Inflammation in small airways is particularly clinically active in severe asthma but the...
SummaryBackgroundThe efficacy and safety of extrafine beclomethasone dipropionate 100 μg/formoterol ...
BACKGROUND: Airway inflammation in asthma involves both large and small airways, and the combination...
Copyright © 2015, Mary Ann Liebert, Inc. 2015.Background: Suppression of small airway inflammation m...
Background: A high strength of beclomethasone/formoterol fumarate (BDP/FF) in a pressurised metered ...
BACKGROUND: Asthma management focuses on achieving and maintaining asthma control. Few studies have ...
Background: A number of single-inhaler triple therapies are being developed for asthma, including th...
Objective: The real-world effectiveness and tolerability of an extrafine fixed dose beclomethasone/f...
BACKGROUND: The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a do...
Aims: To demonstrate the noninferiority of extrafine beclomethasone/formoterol fumarate (BDP/FF) dry...
Asthma guidelines suggest that therapy can be reduced once asthma is controlled. Despite these recom...
AbstractThe objective of this double-blind, randomized, placebo-controlled, parallel-group study was...
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases char...
SummaryBackgroundLung deposition is crucial for asthma treatment. However, there is no study compari...
BACKGROUND: Combinations of a long-acting beta(2)-agonist (LABA) and an inhaled corticosteroid (ICS)...
Background: Inflammation in small airways is particularly clinically active in severe asthma but the...
SummaryBackgroundThe efficacy and safety of extrafine beclomethasone dipropionate 100 μg/formoterol ...
BACKGROUND: Airway inflammation in asthma involves both large and small airways, and the combination...
Copyright © 2015, Mary Ann Liebert, Inc. 2015.Background: Suppression of small airway inflammation m...
Background: A high strength of beclomethasone/formoterol fumarate (BDP/FF) in a pressurised metered ...
BACKGROUND: Asthma management focuses on achieving and maintaining asthma control. Few studies have ...
Background: A number of single-inhaler triple therapies are being developed for asthma, including th...
Objective: The real-world effectiveness and tolerability of an extrafine fixed dose beclomethasone/f...
BACKGROUND: The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a do...
Aims: To demonstrate the noninferiority of extrafine beclomethasone/formoterol fumarate (BDP/FF) dry...
Asthma guidelines suggest that therapy can be reduced once asthma is controlled. Despite these recom...
AbstractThe objective of this double-blind, randomized, placebo-controlled, parallel-group study was...
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases char...
SummaryBackgroundLung deposition is crucial for asthma treatment. However, there is no study compari...
BACKGROUND: Combinations of a long-acting beta(2)-agonist (LABA) and an inhaled corticosteroid (ICS)...